Home/Investors/Cormorant Asset Management

Cormorant Asset Management

Biotech Investor · 10 portfolio companies

Portfolio

10

Focus Areas

12

Top Stage

phase-1

Investment Focus

Genetic Diseases Cardiovascular Oncology Neurodegenerative Diseases Immunology Ophthalmology Neurology Epilepsy Pain Metabolic Genetics & Genomics Rare Disease

Portfolio Companies

Company	Stage	Valuation	Focus
AccurEdit Therapeutics	phase-1	—	Genetic Diseases, Cardiovascular
Scoop	preclinical	—	Oncology, Neurodegenerative Diseases
Numab Therapeutics	phase-2	—	Oncology, Immunology
Atia Vision	Phase 1	—	Ophthalmology
Axonis Therapeutics	Phase 1	—	Neurology, Epilepsy
Jnana Therapeutics	phase-1	—	Immunology, Metabolic
Soufflé Therapeutics	phase-2	—	Oncology, Immunology
ADARx Pharmaceuticals	preclinical	—	Genetics & Genomics, Rare Disease
FogPharma	phase-1	—	Oncology
MOMA Therapeutics	preclinical	—	Oncology

Frequent Co-Investors

Novo Holdings2 shared Legend Capital1 shared Atlas Venture1 shared Versant Ventures1 shared The Column Group1 shared Boxer Capital1 shared Deerfield Management1 shared Sofinnova Investments1 shared